CHRS
Coherus BioSciences Inc
NASDAQ: CHRS · HEALTHCARE · BIOTECHNOLOGY
$1.71
-7.94% today
Updated 2026-06-05
Market cap
$227.52M
P/E ratio
—
P/S ratio
4.84x
EPS (TTM)
$-1.42
Dividend yield
—
52W range
$1 – $3
Volume
1.1M
WallStSmart proprietary scores
47
out of 100
Grade: C
Sell
Investment rating
4.7
Growth
C5.0
Quality
C+4.0
Profitability
C5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-9.1
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$7.80
+356.14%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 397.30% — above average
+ Revenue growth 62.00% QoQ
Risks
- Altman Z -9.14 — distress zone
- Negative free cash flow $-57.89M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $211.04M | $257.24M | $266.96M | $42.17M | $46.88M |
| Net income | $-291.75M | $-237.89M | $28.51M | $-170.29M | $-37.94M |
| EPS | — | — | — | — | $-1.42 |
| Free cash flow | $-243.16M | $-175.17M | $-20.44M | $-138.51M | $-57.89M |
| Profit margin | -138.24% | -92.48% | 10.68% | -403.80% | 397.30% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-01-23 | LANFEAR, DENNIS M | Buy | 750,000 | — |
| 2026-01-23 | LANFEAR, DENNIS M | Buy | 375,000 | — |
| 2026-01-22 | MCMICHAEL, BRYAN J | Buy | 225,000 | — |
Peer comparison
Smart narrative
Coherus BioSciences Inc trades at $1.71. Our Smart Value Score of 47/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -9.14, it sits in the distress. TTM revenue stands at $46.88M. with profit margins at 397.30%.
Frequently asked questions
What is Coherus BioSciences Inc's stock price?
Coherus BioSciences Inc (CHRS) trades at $1.71, on a P/S of 4.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Coherus BioSciences Inc overvalued?
Coherus BioSciences Inc carries a Smart Value Score of 47/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Coherus BioSciences Inc (CHRS)?
The 12-month analyst consensus target is $7.80, about 356.1% above the current $1.71. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Coherus BioSciences Inc's revenue?
Coherus BioSciences Inc's trailing twelve-month revenue is $46.88M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Coherus BioSciences Inc's Altman Z-Score is -9.14, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.84x
ROE-192.90%
Beta0.96
50D MA$1.71
200D MA$1.59
Shares out0.15B
Float0.13B
Short ratio—
Avg volume1.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—